A pharmaceutical tablet comprising a tablet core, wherein the tablet core contains a pharmaceutical composition comprising: (a) from 3 to 70 parts, preferably from 5 to 60 parts, of a pharmaceutical substance; (b) from 5 to 95 parts, preferably from 10 to 85 parts, of a pharmaceutical diluent; (c) from 0.5 to 50 parts, preferably from 0.5 to 45 parts, of a pharmaceutical disintegrant; (d) from 0 to 5 parts, preferably from 0 to 3 parts, of a pharmaceutical solubilizer; and (e) from 0.5 to 5 parts, preferably from 0.5 to 4 parts, of one or more pharmaceutical lubricants; wherein all parts are by weight and a sum of these parts in (a), (b), (c), (d) and (e) is 100; and wherein the pharmaceutical substance is N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H-pyrrolo[3,2-b]pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide or a pharmaceutically acceptable salt thereof; and the pharmaceutical diluent (b) consists of - one component, said one component being microcrystalline cellulose or - multiple components, one of said multiple components being microcrystalline cellulose in a quantity ranging from 10 wt% to 90 wt% of the pharmaceutical diluent; and the pharmaceutical disintegrant (c) consists of - one component, said one component being crospovidone or sodium carboxymethyl starch or - multiple components, one of said multiple components being crospovidone in a quantity ranging from 10 wt% to 90 wt% of the pharmaceutical disintegrant or - multiple components, one of said multiple components being sodium carboxymethyl starch in a quantity ranging from 10 wt% to 50 wt% of the pharmaceutical disintegrant; and the pharmaceutical solubilizer (d) includes any one or more of benzalkonium chloride, benzyl benzoate, cetylpyridinium chloride, cyclodextrin, diethylene glycol monoethyl ether, lecithin, oleyl alcohol, poloxamer, sodium lauryl sulfate, sorbitan tristearate, and glyceryl trioleate. (a) from 3 to 70 parts, preferably from 5 to 60 parts, of a pharmaceutical substance; (b) from 5 to 95 parts, preferably from 10 to 85 parts, of a pharmaceutical diluent; (c) from 0.5 to 50 parts, preferably from 0.5 to 45 parts, of a pharmaceutical disintegrant; (d) from 0 to 5 parts, preferably from 0 to 3 parts, of a pharmaceutical solubilizer; and (e) from 0.5 to 5 parts, preferably from 0.5 to 4 parts, of one or more pharmaceutical lubricants; wherein all parts are by weight and a sum of these parts in (a), (b), (c), (d) and (e) is 100; and wherein the pharmaceutical substance is N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H-pyrrolo[3,2-b]pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide or a pharmaceutically acceptable salt thereof; and the pharmaceutical diluent (b) consists of - one component, said one component being microcrystalline cellulose or - multiple components, one of said multiple components being microcrystalline cellulose in a quantity ranging from 10 wt% to 90 wt% of the pharmaceutical diluent; and - one component, said one component being microcrystalline cellulose or - multiple components, one of said multiple components being microcrystalline cellulose in a quantity ranging from 10 wt% to 90 wt% of the pharmaceutical diluent; and the pharmaceutical disintegrant (c) consists of - one component, said one component being crospovidone or sodium carboxymethyl starch or - multiple components, one of said multiple components being crospovidone in a quantity ranging from 10 wt% to 90 wt% of the pharmaceutical disintegrant or - multiple components, one of said multiple components being sodium carboxymethyl starch in a quantity ranging from 10 wt% to 50 wt% of the pharmaceutical disintegrant; and - one component, said one component being crospovidone or sodium carboxymethyl starch or - multiple components, one of said multiple components being crospovidone in a quantity ranging from 10 wt% to 90 wt% of the pharmaceutical disintegrant or - multiple components, one of said multiple components being sodium carboxymethyl starch in a quantity ranging from 10 wt% to 50 wt% of the pharmaceutical disintegrant; and the pharmaceutical solubilizer (d) includes any one or more of benzalkonium chloride, benzyl benzoate, cetylpyridinium chloride, cyclodextrin, diethylene glycol monoethyl ether, lecithin, oleyl alcohol, poloxamer, sodium lauryl sulfate, sorbitan tristearate, and glyceryl trioleate.